West Pharmaceutical Services, Inc. (WST)
West Pharmaceutical Services, Inc. (WST) Hit a 52 Week High, Can the Run Continue?
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
West Pharmaceutical Services (WST) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, West Pharmaceutical Services, Inc. (WST) is looking like an interesting pick, as it just reached a key level of support. WST's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength.
Are You Looking for a Top Momentum Pick? Why West Pharmaceutical Services (WST) is a Great Choice
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
From Slide to Surge: How West Pharmaceutical Services Reclaimed Its Mojo in 2026
West Pharmaceutical Services (NYSE: WST | WST Price Prediction) has ripped 24.2% in the past month and 8.7% in the past week, and the move has the fingerprints of a sustained re-rating.
Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
West Pharmaceutical: A High-Quality Beat-And-Raise With More Upside Ahead
West Pharmaceutical Services delivered a beat-and-raise 1Q26, with adjusted EPS of $2.13 and revenue of $844.9M, both well ahead of expectations. WST's growth is driven by robust demand for High-Value Product components, biologics, and a favorable mix shift, supporting margin expansion and durable earnings momentum. Management raised FY26 guidance to $3.35B revenue and $8.75 adjusted EPS, reflecting operational strength but maintaining a conservative outlook amid macro uncertainties.
WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth
West Pharmaceutical posts 46.9% EPS growth and beats estimates as strong segment demand lifts revenues, prompting a higher 2026 outlook and margin expansion.
West Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Call Transcript
West Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Call Transcript
Compared to Estimates, West Pharmaceutical (WST) Q1 Earnings: A Look at Key Metrics
The headline numbers for West Pharmaceutical (WST) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.45 per share a year ago.
